Pharmaceutical company Axsome Therapeutics announced strong financial results for the third quarter of 2026, with significant implications for people managing sleep apnea and related sleep disorders. The company’s revenue growth and expanded prescription volumes signal increasing availability and recognition of treatment options for daytime sleepiness associated with obstructive sleep apnea.

Record Growth in Sleep Apnea Medication Prescriptions

Axsome’s lead sleep medicine product, SUNOSI, achieved net revenue of $48.2 million during the third quarter, marking a 47% increase compared to the same period in 2025. More importantly for consumers, the company wrote approximately 64,400 prescriptions for the medication in the United States during the quarter, reflecting a 15% year-over-year climb and a 6% increase from the previous quarter.

SUNOSI is a dopamine and norepinephrine reuptake inhibitor designed to address excessive daytime sleepiness in people with obstructive sleep apnea or narcolepsy. The medication works by helping regulate neurotransmitters that control wakefulness and alertness. As recent surveys have highlighted the widespread nature of sleep apnea among various populations, expanded prescription growth indicates more clinicians are diagnosing and treating the condition.

Improved Insurance Coverage and Accessibility

woman waking up refreshed morning
Photo by bruce mars

A critical factor affecting whether consumers can actually fill SUNOSI prescriptions is insurance coverage. Axsome reported that payer coverage for SUNOSI currently stands at approximately 82% of all covered lives. This breaks down to 97% of commercial insurance plans and 59% of government-sponsored insurance programs. This expanded coverage means more patients with health insurance have access to the treatment without facing prohibitive out-of-pocket costs.

The growing prescription volume reflects both increased clinical awareness of sleep apnea treatment options and improving reimbursement landscapes. For shoppers navigating treatment decisions, improved insurance coverage translates to more affordable access to FDA-approved medication designed specifically for daytime sleepiness related to sleep apnea.

Beyond SUNOSI’s commercial growth, Axsome is advancing multiple investigational treatments targeting narcolepsy and shift work disorder. The company submitted a new drug application to the FDA for AXS-12, a candidate treatment for cataplexy in narcolepsy patients. The FDA’s target decision date is set for May 1, 2027. Cataplexy is a debilitating symptom involving sudden muscle weakness triggered by emotion.

The company is also conducting a phase 3 clinical trial called SUSTAIN, evaluating solriamfetol for shift work disorder, with topline results anticipated in the second half of 2027. These pipeline advancements suggest that consumers may have additional treatment options in coming years for various sleep-related conditions.

What This Means for Sleep Apnea Shoppers

Rising prescription volumes and revenue growth for SUNOSI indicate several positive trends for consumers dealing with sleep apnea. First, increased clinical adoption means more healthcare providers are screening for and diagnosing the condition, reducing the likelihood that sleep apnea goes unrecognized. Second, expanded insurance coverage makes approved treatments more affordable and accessible. Third, continued pharmaceutical investment in sleep medicine suggests sustained development of new and improved therapeutic options.

While generic alternatives have also become available for some sleep apnea medications, brand-name treatments like SUNOSI offer specific mechanisms of action and may be appropriate for certain patient populations. The medication’s 47% revenue growth reflects both market expansion and increased patient demand.

Managing Costs and Coverage

pharmacist reviewing medication bottles
Photo by National Cancer Institute

For consumers currently using or considering SUNOSI, understanding your specific insurance coverage is essential. With 82% overall coverage among insured populations, most people will have some level of reimbursement, though actual out-of-pocket costs depend on individual plan details, deductibles, and copay structures. Patients should discuss medication options with their healthcare provider and verify coverage with their insurance company before filling prescriptions.

Additionally, ongoing research continues to identify risk factors and patient populations most likely to benefit from treatment, helping clinicians tailor recommendations to individual circumstances.

Looking Ahead

The strong financial performance of Axsome’s sleep medicine portfolio reflects a broader trend toward recognizing and treating sleep apnea as a significant health concern. As more people receive diagnoses and treatment options expand, the landscape for managing daytime sleepiness and related symptoms continues to improve. For shoppers evaluating treatment options, this growth cycle translates to better availability, improved insurance support, and ongoing development of new therapies.